Pharma’s Oncology Targeting Model Is Missing Part of the Care Team

New data from McKesson Compile shows that nurse practitioners (NPs) and physician assistants (PAs) are playing an increasingly prominent role in the oncology treatment landscape. And few pharma companies may have a clear picture of who these providers are, where they practice, or which cancer patients they treat. This isn’t just an issue for sales targeting. Medical Affairs, MSL deployment, HCP education, omnichannel strategy, and more are impacted by how well pharmaceutical companies understand and engage these providers.

One in Four Oncology HCPs May Be an NP or PA

The headline statistic deserves attention. McKesson estimates that approximately one in four oncology healthcare professionals is an NP or PA. There are structural reasons for their growing importance.

Cancer cases are increasing while the number of oncologists remains relatively flat. At the same time, a growing population of cancer survivors requires long-term follow-up, monitoring, and coordination across specialists. Oncology itself has also become increasingly multidisciplinary and team-based.

The result is that advanced practice providers are taking on responsibilities that can put them directly in the middle of the patient journey.

According to the report, oncology NPs and PAs may manage routine and follow-up care, monitor treatment adherence, educate patients and caregivers, provide psychosocial support, and prescribe treatments and supportive care. These aren’t peripheral activities. They are fundamental components of cancer care.

Yet Pharma May Not Know Who These Providers Are

And that’s where taxonomy codes start to matter for biopharma. Legacy provider databases will often use taxonomy codes to define HCP specialties. That’s fine if you’re talking about a medical oncologist. Not so much for an NP or PA. McKesson points out that taxonomy codes for Nurse Practitioners and Physician Assistants aren’t necessarily reflective of their clinical specialty.

An NP who treats breast cancer patients on a daily basis may just show up as an NP in traditional provider-reference or affiliation data. You have the provider identified in your database. What may be missing is what makes that provider valuable: clinical practices that align with your products. Like oncology in the example above. And it could be many providers. More than 1,000 oncology NPs and PAs across the 20 largest health systems profiled in the study could be missed by traditional taxonomy-based reference and affiliation tools.

Nearly 12,000 Oncology NPs and PAs

McKesson’s Provider 360 ReadyData analysis provides a sense of the scale.

As of June 2025, it identified approximately:

  • 11,850 NPs and PAs practicing in oncology
  • 11,770 oncology NPs and PAs with affiliation information
  • 38,670 HCPs with data identifying cancer types treated

McKesson also reports that NPs and PAs make up nearly 20% of oncology brand target lists. Think about what that means.

A pharma company could have a sophisticated oncology segmentation model, carefully constructed call plans, an expensive CRM infrastructure, extensive claims data, and an elaborate omnichannel strategy—and still have an incomplete understanding of the people actually managing its patients. That’s not primarily a data problem. It’s a targeting-model problem.

Stop Asking Only “Who Is the Oncologist?”

The more intriguing insight from the McKesson analysis, however, may be that pharma will need to think differently about who an important oncology HCP is. Traditionally, targeting has understandably been physician-centric because docs made the majority of treatment decisions and wrote the scrips. But modern oncology care is increasingly a clinical ecosystem vs. a physician-patient pair. An individual patient may see an oncologist, NP, PA, pharmacist, nurse, and various specialists throughout their care experience.

Different HCPs can have influence over different parts of the treatment process. The oncologist may decide on the overall treatment plan, but another provider may spend significantly more time on things like discussing adverse events, reinforcing adherence, educating the patient, monitoring the therapy, or managing supportive care. So maybe the better targeting question is: Who has influence over the treatment and management of this patient? That query yields a much larger group of HCPs.

The Implications for MSLs Are Particularly Important

Medical Affairs leaders should be taking note. Much of MSL strategy starts with physician-centric identification of KOLs. However, if APDs are taking on larger roles in managing treatment and educating/prescribing for patients, some will undoubtedly qualify as highly valuable scientific relationships. In fact, the report explicitly mentions MSL education as a use case for improved oncology HCP intelligence, suggesting that more granular provider data can help pinpoint exactly who should receive scientific and educational outreach.

My question to Medical Affairs is this: How many key oncology NPs and PAs are not currently on MSL stakeholder maps simply because the data sets used to create those maps don’t recognize those NPs and PAs as oncologists? An MSL strategy designed around a narrow and outdated definition of influence may be missing key players with significant influence on patient care today.

Disease-Level Data Changes the Equation

McKesson’s approach is also enlightening. Instead of provider taxonomy, its Provider 360 ReadyData product identifies practicing specialty by analyzing real-world prescription and diagnosis activity. McKesson also identifies the cancer types providers most commonly manage by analyzing diagnosis patterns across medical claims and other sources. Conceptually, this is a big leap forward. Instead of knowing:
Jane Smith — Nurse Practitioner, a company can know: Jane Smith — NP — Oncology — sees patients with breast cancer — affiliated with Health System X. The second profile is many times more useful to sales, marketing, and Medical Affairs teams. It moves targeting beyond credentials and into actual clinical behavior. And that may be the direction oncology targeting must head.

Pharma Needs to Map the Patient’s Care Network

Pharma has made big investments towards being patient-centric. But there’s some irony in that. You can’t fully understand the patient journey without understanding all the HCPs who influence that journey. So the next generation of oncology targeting shouldn’t just produce better lists of oncologists. It should map out the patient’s care network. Who starts the patient on therapy? Who influences treatment selection? Who educates the patient? Who monitors AE’s? Who manages supportive care? Who reinforces adherence? Who sees the patient between doctor visits? And who is actually writing the Rx? Once we start building targeting platforms around those questions, then the old concept of a “primary target” and “non-target” will begin to look silly.

Elephant In The Room

It should go without saying that McKesson is announcing this study in order to tout its Provider 360 ReadyData data product. That’s fine. Context is important. My point isn’t about McKesson. It’s about how we target physicians in oncology.

Regardless of what data vendor you prefer, we need to recognize that oncology care is different from what it was even a few years ago. Our methods for identifying who to talk to should be different, too. We’re great at identifying physicians who specialize in oncology. We can easily calculate their prescribing potential. We know how to reach the majority of them with promotion.

Maybe what we need to get better at is identifying everyone who has a significant impact on the patient’s treatment decision-making process—and defining each person’s unique role. If 1 in 4 oncology physicians are actually NPs or PAs, then companies that only focus on “targeting the oncologist” aren’t just leaving names off their target lists. They’re ignoring a large piece of the oncology care team.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply